[Form 4] Climb Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Susan Altschuller, Chief Financial Officer of Climb Bio, Inc. (CLYM), received a stock option grant on October 1, 2025. The option gives the right to buy 600,000 shares of common stock at an exercise price of $1.97 per share and is exercisable through September 30, 2035. The option vests 25% on the first anniversary of the grant and the remainder in 36 equal monthly installments through October 1, 2029, subject to continued service. The reported ownership following the grant is 600,000 shares, held directly.

Positive

• 600,000-share option grant aligns the CFO's incentives with long-term shareholder value
• Multi-year vesting schedule (25% after one year, remainder over 36 months) supports retention
• Direct ownership of the option reported, providing transparent disclosure

Negative

• Potential dilution if 600,000 options are exercised
• Long-term vesting delays potential shareholder alignment until service conditions are met
• No board approval details or comparative compensation benchmarks are provided in this filing

Insights

Financial Analyst

TL;DR: A sizable option award aligns the CFO with shareholder value but will dilute if exercised.

The 600,000-share option at $1.97 is a meaningful compensation event for a company of typical clinical-stage biotech scale. It aligns management incentives with long-term share performance given the lengthy 10-year term and multi-year vesting schedule. Investors should note the direct ownership of 600,000 shares post-grant and the potential dilution if options are exercised, though the schedule ties realized value to sustained service and future stock appreciation.

Corporate Governance Expert

TL;DR: Grant appears standard for executive retention; vesting conditions emphasize continued service.

The option structure—25% cliff after one year then monthly vesting over three years—follows common retention-focused design. The grant was reported on Form 4 and executed by an attorney-in-fact, indicating proper disclosure processes. There is no disclosure of board approval details or comparative peer benchmarks in this filing, so governance context is limited to the award terms presented.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

ALTSCHULLER Susan

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MA 02481

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.97	10/01/2025		A		600,000		(1)	09/30/2035	Common Stock	600,000	$0.00	600,000	D

Explanation of Responses:

1. This option was granted on October 1, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date, and the remainder are scheduled to vest in 36 equal monthly installments through October 1, 2029, subject to the Reporting Person's continued service.

	/s/ Chandra Adams, as Attorney-in-Fact	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Susan Altschuller report on Form 4 for CLYM?

The CFO reported a stock option grant for 600,000 shares exercisable at $1.97 per share.

When was the option grant for CLYM reported and what is the exercise price?

The option was granted on October 1, 2025 with an exercise price of $1.97 per share.

What is the vesting schedule and expiration date of the CLYM option?

The option vests 25% after one year and the remainder in 36 equal monthly installments through October 1, 2029; expiration is September 30, 2035.

How many shares does the reporting person beneficially own after the transaction?

The filing reports beneficial ownership of 600,000 shares following the reported transaction.

What is the ownership form reported on the Form 4?

The ownership form is reported as Direct (D).